Fusion Antibodies PLC
LSE:FAB
Gross Margin
Fusion Antibodies PLC
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Gross Margin Comparison
Fusion Antibodies PLC Competitors
Country | UK |
Market Cap | 3.6m GBP |
Gross Margin |
-7%
|
Country | US |
Market Cap | 224.7B USD |
Gross Margin |
40%
|
Country | US |
Market Cap | 184.6B USD |
Gross Margin |
59%
|
Country | JP |
Market Cap | 16.9T JPY |
Gross Margin |
22%
|
Country | US |
Market Cap | 45.9B USD |
Gross Margin |
35%
|
Country | KR |
Market Cap | 59.3T KRW |
Gross Margin |
49%
|
Country | CH |
Market Cap | 39B CHF |
Gross Margin |
36%
|
Country | US |
Market Cap | 42.6B USD |
Gross Margin |
51%
|
Country | US |
Market Cap | 29.1B USD |
Gross Margin |
38%
|
Country | US |
Market Cap | 28.7B USD |
Gross Margin |
59%
|
Country | IE |
Market Cap | 27.7B USD |
Gross Margin |
30%
|
Gross Margin Distribution
Gross Margin Distribution
Life Sciences Tools & Services Industry
Profitability Report
View the profitability report to see the full profitability analysis for Fusion Antibodies PLC.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Fusion Antibodies PLC's most recent financial statements, the company has Gross Margin of -7.4%.